KY-9 is an antibacterial active compound.

FCE-20696 (hydrochloride) is an orally active immunomodulator. FCE-20696 (hydrochloride) also shows anti-inflammation and anti-infection effects. FCE-20696 (hydrochloride) can be used for the researches of infection, inflammation and immunology, such as adjuvant arthritis.

CP-74667 is a quinolone antibacterial agent. CP-74667 shows high activity against Xanthomonas maltophilia (MIC50 = 1 μg/mL), Staphylococcus spp. (MIC50 = 0.06-0.12 μg/mL) and enterococci (MIC50 = 0.5-4 μg/mL).

E 5065 is an orally active antibacterial agent. E 5065 exhibits potent in vitro activity against Gram-negative microorganisms, Gram-positive cocci, and anaerobes. E 5065 exhibits an MIC90 of 0.5 μg/mL against Clostridium spp. E 5065 provides protection against experimental infections caused by P. aeruginosa.

ML370 is an antibacterial agent. ML370 exerts antibacterial activity by inhibiting the activity of Vibrio cholerae LuxO kinase. ML370 can be used in the research of infectious diseases such as cholera.

ABT-255 free base is an orally active anti-bacterial agent. ABT-255 free base exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin- or Ethambutol-resistant Mycobacterium tuberculosis. ABT-255 free base shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 free base can be used for the study of pulmonary tuberculosis.

KP 736 (sodium) is a broad-spectrum antibacterial agent. KP 736 (sodium) exhibits excellent broad-spectrum anti Gram negative bacterial activity in vitro, especially effective against Pseudomonas aeruginosa and multiple drug-resistant bacteria. KP 736 (sodium) can be used for research on bacterial infections.

Bacillibactin (Corynebactin) is a cyclic tricatecholate siderophore. Bacillibactin’s primary function is to facilitate bacterial iron acquisition by chelating iron ions (Fe3+) from the environment, thereby aiding bacterial survival under iron-limited conditions. Bacillibactin exhibits direct antimicrobial activity, such as inhibition of the growth of the producing bacteria Pseudomonas aeruginosa and Aeromonas veronae, as well as plant pathogens such as Pseudomonas syringae.Bacillibactin can be used in antibacterial and antifungal research.

LY 255262 is an antibacterial agent. LY 255262 exhibits potent inhibitory effects against a variety of Gram-positive and Gram-negative bacteria in vitro. LY 255262 has MIC values of 64, 0.25, 0.5, 0.25, 0.25, 1, and 1 μg/mL for Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza, Escherichia coli, Klebsiella, Enterobacter aerogenes, and Serratia, respectively. LY 255262 has a relatively weak inhibitory effect on Pseudomonas (MIC >128 μg/mL). LY 255262 can be used in antibacterial research.

MC-207110 is a broad-spectrum efflux pump inhibitor. MC-207110 is active against all three known Mex efflux pumps from P. aeruginosa and their close Escherichia coli efflux pump homolog (AcrAB-TolC). MC-207110 can decrease the intrinsic resistance of P. aeruginosa to fluoroquinolones. MC-207110 can be used for the research of infection .

MC-04124 is an efflux pump inhibitor. MC-04124 significantly enhances the activity of Levofloxacin against Pseudomonas aeruginosa.

NLCQ-1 (NSC 709257) is an orally active antibacterial agent targeting dormant Mycobacterium tuberculosis. NLCQ-1 is promising for research of tuberculosis.

HC2210 has an antibacterial effect against Mycobacterium abscessus (Mab) (EC50: 0.72 µM). HC2210 modulates the expression of Mab genes related to oxidative stress and lipid metabolism. HC2210 can be used in the study of Mab infection.

AR-102 has inhibitory activity towards Staphylococcus aureus. AR-102 exhibits a competitive potent inhibition of the F98Y mutant DHFR (Ki = 0.22 nM). AR-102 has been determined as ternary complex with NADPH in both wild-type S. aureus DHFR and the TMP-resistant F98Y mutant enzyme.

TXA497 is a potent local topical bactericide. TXA497 exerts its bactericidal effect by interfering with the polymerization kinetics of the bacterial cell division protein FtsZ, rather than inhibiting it. TXA497 shows strong activity against various Staphylococcus aureus strains, including MRSA and MSSA, with an MIC value ranging from 1.0 to 2.0 μg/mL. TXA497 skin deposition is concentration-dependent in its formulation, consistent with Fick's first law. TXA497 has limited systemic permeability through the lipid pathway of the stratum corneum and is easily absorbed through this route. TXA497 can be used for research on topical bactericidal agents.

S-0636 is a novel glutamyl cyclase (QC) inhibitor characterized by high selectivity, low cytotoxicity, and difficulty in inducing drug resistance. S-0636 can effectively inhibit the virulence factors of P. gingivalis. S-0636 can be used for research on bacterial infections.

Neomycin C hexaacetate, a tetracyclic antibacterial agent, is a major active isomeric components of the Neomycin complex. Neomycin, is a 2-DOS-containing aminoglycoside, consisting of Neomycin A, Neomycin B, and Neomycin C.

CP-5068is a cell wall inhibitor that can be used for the study of infectious diseases.

PGE 9262932 is a quinolone antibacterial agent. PGE 9262932 can be used for the research of infection.

WCK-1152 is a fluoroquinolone antibacterial agent. WCK-1152 is active against resistant pathogens bearing mutations of DNA gyrase and/or topoisomerase IV which also express efflux pumps. WCK-1152 can be used for the research of infection, such as respiratory infections caused by resistant pneumococci and staphylococci.

DC-756 is a fluoroquinolone antibiotic. DC-756 possesses potent activity against Gram-positive and Gram-negative pathogens comparable to Trovafloxacin, with MIC, against Ofloxacin-resistant strains 16-fold better than Trovafloxacin. DC-756 is well absorbed orally in rats and found to have good photostability. DC-756 can be used to study bacterial resistance.

4'-Acetyl-chrysomycin A is an analog of chrysomycin A. 4'-Acetyl-chrysomycin A has antibacterial activity.

WR 151327 is an orally active radiation and chemoprotection protector. WR 151327 can suppress expression of HIV. WR 151327 can be used for the researches of infection and cancer.

GaSal-2 is a water-soluble anti-pseudomonal agent that targets the extracellular hemocyte HasAp. It binds tightly to HasAp, blocks the transcriptional activation of the bacterial cell surface signaling cascade, and inhibits the growth of Pseudomonas aeruginosa.

IMB-881 is an antibacterial agent. IMB-881 binds to LptA to inhibit the interaction between LptA and LptC. IMB-881 shows potent antibacterial activity against Gram-negative bacteria.

JNJ-6640 is an inhibitor targeting mycobacterial PurF (the first enzyme in the de novo purine biosynthesis pathway) with potent anti-tuberculosis activity. JNJ-6640 exhibits bactericidal activity against Mycobacterium tuberculosis in vitro, with an MIC90 of 8.6 nM. JNJ-6640 disrupts de novo purine biosynthesis, inhibits M. tuberculosis DNA replication in vivo. JNJ-6640 exhibits anti-tuberculosis efficacy in acutely infected mice. JNJ-6640 can be used for the study of tuberculosis.

Debio 1453 is a bactericidal FabI inhibitor potent against N. gonorrhoeae (IC50 = 0.6 nM), including drug-resistant strains. Debio 1453 demonstrates a low propensity for resistance selection and is effective in eradicating both planktonic and intracellular bacteria through a mechanism of concurrently inhibiting FabI and engaging the non-mutable NADH cofactor. Debio 1453 clears antibiotic-resistant N. gonorrhoeae infection in a murine vaginal model. Debio 1453 can be used for gonorrhoea research.

BMY-28271 is an orally active cephalosporin. BMY-28271 has a widely expanded spectrum with high activity against gram-positive and gram-negative bacteria. BMY-28271 is a poor substrate for various beta-lactamases. BMY-28271 can be used for the research of infection.

U-97456 is a N-hydroxyacetyl derivate with antibacterial activity. U-97456 shows MIC <50 μg/mL against M. tuberculosis H37Rv. U-97456 can be used for the research of infection.

PNU-140457 is an antibacterial agent targeting 30S ribosomal subunit. PNU-140457 is promising for research of bacterial Infections.